GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » Common Stock

Advagene Biopharma Co (ROCO:6709) Common Stock : NT$533.80 Mil (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co Common Stock?

Advagene Biopharma Co's quarterly common stock increased from Jun. 2023 (NT$493.49 Mil) to Dec. 2023 (NT$533.80 Mil) but then stayed the same from Dec. 2023 (NT$533.80 Mil) to Jun. 2024 (NT$533.80 Mil).

Advagene Biopharma Co's annual common stock increased from Dec. 2021 (NT$492.92 Mil) to Dec. 2022 (NT$493.49 Mil) and increased from Dec. 2022 (NT$493.49 Mil) to Dec. 2023 (NT$533.80 Mil).


Advagene Biopharma Co Common Stock Historical Data

The historical data trend for Advagene Biopharma Co's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co Common Stock Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial 443.87 541.99 492.92 493.49 533.80

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 493.49 493.49 493.49 533.80 533.80

Advagene Biopharma Co Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Advagene Biopharma Co Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co Headlines

No Headlines